News Eisai Co., Ltd.

Equities

4523

JP3160400002

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-07 am EDT			5-day change	1st Jan Change
6,595 ^JPY	+0.76%		+5.69%	-6.48%

May. 06	People with two copies of a risk gene have genetic form of Alzheimer's, scientists say	RE
Apr. 24	Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

People with two copies of a risk gene have genetic form of Alzheimer's, scientists say	May. 06	RE
BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024	Apr. 25	AQ
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024	Apr. 24	AQ
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Alzheimer's drug adoption in US slowed by doctors' skepticism	Apr. 23	RE
BioArctic and Eisai sign research evaluation agreement regarding BAN2802	Apr. 20	AQ
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802	Apr. 20	CI
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)	Apr. 17	AQ
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan	Apr. 17	AQ
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?	Apr. 13	AQ
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics	Apr. 03	AQ
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	Apr. 01	MT
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	Apr. 01	MT
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	AQ
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed	Mar. 31	AQ
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	CI
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical	Mar. 29	AQ
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture	Mar. 29	AQ
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024	Mar. 29	AQ
Final dividend	Mar. 27	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Eisai Co., Ltd.

Equities

4523

JP3160400002

Summary

Filters